Sep. 9 at 1:19 AM
$KURA I think this is really good news for Kura too
https://www.healthcare-brew.com/stories/oncologists-say-newly-approved-pancreatic-cancer-drug-is-a-breakthrough-for-treatment
This is potentially very good for
$KURA. Daraxonrasib just showed that targeting RAS can be a major breakthrough in pancreatic cancer. Kura plans to test its drug darlifarnib in combination with daraxonrasib.
The idea is simple: daraxonrasib attacks the cancer, while darlifarnib may block an escape/resistance pathway and make the treatment work better and longer.
Kura already saw a 67% response rate with darlifarnib + another KRAS inhibitor in a tiny pancreatic cancer study. Very early data, but encouraging.
So daraxonrasib succeeding doesn't compete with Kura — it potentially gives Kura a powerful, validated drug to combine with.
If the combination works, darlifarnib could become much more than a small pipeline asset.
$KURA
